Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 36 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• Pembrolizumab + Idelalisib for Lung Cancer StudyTerminatedNCT03257722Phase 1/2Results posted
• Study of Cemiplimab in Adults With Cervical CancerCompletedNCT03257267Phase 3Results posted
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCCompletedNCT03256136Phase 2Results posted
• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasCompletedNCT03255018Phase 2Results posted
• Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1Results posted
• Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT03250299Phase 1Results posted
• A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaCompletedNCT03250273Phase 2Results posted
• Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)TerminatedNCT03249792Phase 1Results posted
• Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsCompletedNCT03248570Phase 2Results posted
• Nivolumab Plus Ipilimumab in Thyroid CancerCompletedNCT03246958Phase 2Results posted
• Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsCompletedNCT03242915Phase 2Results posted
• Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)TerminatedNCT03241927Phase 2Results posted
• A Study of Nivolumab in Selected Uterine Cancer PatientsCompletedNCT03241745Phase 2Results posted
• PD-1 Inhibition to Determine CNS Reservoir of HIV-InfectionCompletedNCT03239899Phase 1Results posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• Focused Ultrasound and Pembrolizumab in Metastatic Breast CancerTerminatedNCT03237572Phase 1Results posted
• Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerTerminatedNCT03237377Phase 2Results posted
• Phase Ib of L-NMMA and PembrolizumabCompletedNCT03236935Phase 1Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingNCT03233347Phase 2Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma PatientsCompletedNCT03228836Phase 2Results posted
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaActive, not recruitingNCT03228537Phase 1Results posted
• PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin LymphomaActive, not recruitingNCT03226249Phase 2Results posted
• Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesCompletedNCT03222856Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerCompletedNCT03222076Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)CompletedNCT03221426Phase 3Results posted
• Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung CancerCompletedNCT03217071Phase 2Results posted
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results posted
• A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedNCT03215706Phase 3Results posted
• RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersActive, not recruitingNCT03215095Early Phase 1Results posted
• Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT03214250Phase 1/2Results posted
• Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerCompletedNCT03213041Phase 2Results posted
• Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver CancerCompletedNCT03211416Phase 1/2Results posted
• Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid CancerCompletedNCT03211117Phase 2Results posted
• Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03210662Phase 2Results posted
• A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03209973Phase 2Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast CancerCompletedNCT03206203Phase 2Results posted
• Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03206047Phase 1/2Results posted
• Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03204812Phase 2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)Active, not recruitingNCT03203473Phase 2Results posted
• Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerCompletedNCT03201458Phase 2Results posted
• Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaCompletedNCT03200847Phase 1/2Results posted
• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerTerminatedNCT03199885Phase 3Results posted
• A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerCompletedNCT03197935Phase 3Results posted
• Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaActive, not recruitingNCT03197506Phase 2Results posted
• Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerCompletedNCT03197467Phase 2Results posted
• Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.CompletedNCT03197389Early Phase 1Results posted
• Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric CancerCompletedNCT03196232Phase 2Results posted
• A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaCompletedNCT03195491Phase 3Results posted
• A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT03195478Phase 1/2Results posted
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedNCT03194867Phase 1/2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedNCT03193190Phase 1/2Results posted
• A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet ChemotherapyCompletedNCT03191786Phase 3Results posted
• Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerCompletedNCT03190265Phase 2Results posted
• Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine CarcinomaTerminatedNCT03190213Phase 2Results posted
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersCompletedNCT03190174Phase 1/2Results posted
• First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)CompletedNCT03189719Phase 3Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03184571Phase 2Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedNCT03184558Phase 2Results posted
• Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLCCompletedNCT03181308Phase 1Results posted
• Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaActive, not recruitingNCT03179917Phase 2Results posted
• Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)CompletedNCT03179436Phase 1/2Results posted
• PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate CancerCompletedNCT03179410Phase 2Results posted
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaCompletedNCT03178851Phase 1Results posted
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03174275Phase 2Results posted
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT03174197Phase 1/2Results posted
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results posted
• Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerCompletedNCT03172624Phase 2Results posted
• Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)TerminatedNCT03168464Phase 1/2Results posted
• Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
• Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT03167151Phase 1/2Results posted
• A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have SpreadTerminatedNCT03166631Phase 1Results posted
• Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingNCT03164616Phase 3Results posted
• Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of SorafenibCompletedNCT03163992Phase 2Results posted
• GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic CancerCompletedNCT03161379Phase 2Results posted
• Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsCompletedNCT03160079Phase 1/2Results posted
• Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerCompletedNCT03158129Phase 2Results posted
• Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
• This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.CompletedNCT03156114Phase 1Results posted
• PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's LymphomaCompletedNCT03155425Phase 2Results posted
• Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the PancreasCompletedNCT03153410Early Phase 1Results posted
• A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLCCompletedNCT03150875Phase 3Results posted
• Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.Active, not recruitingNCT03150329Phase 1Results posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingNCT03149029Phase 2Results posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results posted
• A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix CancerTerminatedNCT03144466Phase 1Results posted
• A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedNCT03143153Phase 3Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)CompletedNCT03142334Phase 3Results posted
• Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCActive, not recruitingNCT03141359Phase 2Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsTerminatedNCT03138889Phase 1/2Results posted
• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCompletedNCT03138512Phase 3Results posted
• Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasCompletedNCT03136055Phase 2Results posted

← Immune Checkpoint Inhibitors overview